Veit Bücklein - Concepedia

Author

Veit Bücklein

Ludwig-Maximilians-Universität München ORCID

Also Known As

Bücklein, Veit, Bücklein, Veit Leonhard, Pere Barba, V Bücklein, V. Bücklein, V. L. Bücklein, Veit Bücklein, Veit Bücklein, Veit L Bücklein, Veit L. Bücklein

157

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Ludwig-Maximilians-Universität München LMU Klinikum Heidelberg University German Cancer Research Center Helmholtz Zentrum München

About

Veit Bücklein is an author at Ludwig-Maximilians-Universität München specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	19	1.5K
2	Health Sciences	8	8	1.1K
3	Blood Transplantation	3	3	106
4	Allergy	2	2	85
5	Public Health	1	1	17

Veit Bücklein

Publications

Citations

H-Index

Page 1

	Year	Citations
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele, Blood Mixed-phenotype Acute LeukemiaPathologyMeasurable Residual DiseaseMyeloid NeoplasiaHematological Malignancy	2021	666
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma Kai Rejeski, Ariel Perez Perez, Pierre Sesques, Blood	2021	398
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals Nora Philipp, Maryam Kazerani, Alyssa Nicholls, Blood T-regulatory CellImmunologyImmunologic MechanismT CellsImmunotherapy	2022	215
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni, Journal for ImmunoTherapy of Cancer	2022	169
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Marion Subklewe, Anthony S. Stein, Roland B. Walter, Blood	2019	86
Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings Johanna Tischer, Nicole Engel, Susanne Fritsch, Annals of Hematology VaccinationTransplantationViral PersistenceVirus InfectionStem Cell Transplantation	2015	70
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy Kai Rejeski, Andreas Burchert, Gloria Iacoboni, Blood Advances	2022	63
Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study Marion Subklewe, Giulia Magno, Christina Gebhardt, European Journal of Cancer	2024	63
Diagnosis of <scp>CLL</scp> revisited: increased specificity by a modified five‐marker scoring system including <scp>CD</scp>200 Thomas Köhnke, Veronika K. Wittmann, Veit Bücklein, British Journal of Haematology	2017	62
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE Patrick Schöffski, Michaela Kubičková, Agnieszka Woźniak, European Journal of Cancer	2021	59

Page 1